Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

24.99 -0.01 (-0.04%)

Official Closing Price Updated: 4:10 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

July 23, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks

July 23, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound ↗

July 23, 2025

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

Via MarketBeat

Topics Artificial Intelligence

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗

July 23, 2025

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

Via Investor's Business Daily

Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours ↗

July 17, 2025

Via Stocktwits

1 Mid-Cap Stock on Our Buy List and 2 We Avoid

July 23, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off

July 22, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade ↗

July 21, 2025

Via The Motley Fool

Topics Intellectual Property

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

July 21, 2025

Via Benzinga

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? ↗

July 20, 2025

Via The Motley Fool

Topics Economy Intellectual Property

5 High-Yield Stock Picks to Add to Your Dividend Portfolio ↗

July 20, 2025

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth.

Via The Motley Fool

2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now ↗

July 19, 2025

Via The Motley Fool

Topics Retirement

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off ↗

July 17, 2025

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery.

Via Benzinga

Which S&P500 stocks are the most active on Thursday? ↗

July 17, 2025

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market...

Via Chartmill

1 Cash-Producing Stock with Competitive Advantages and 2 to Avoid

July 17, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks

July 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback ↗

July 16, 2025

Via The Motley Fool

Don’t Miss These 4 Stocks With Explosive Dividend Yields ↗

July 15, 2025

Via MarketBeat

Topics Stocks

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook ↗

July 14, 2025

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Via Benzinga

Topics Intellectual Property

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

3 S&P 500 Stocks in Hot Water

July 14, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony ↗

July 11, 2025

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.

Via Benzinga

Topics Lawsuit

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Years ↗

July 10, 2025

Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré...

Via Stocktwits

Topics Death Lawsuit

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Via Benzinga

An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?' ↗

July 10, 2025

Via Benzinga

Topics Economy Government

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months ↗

July 10, 2025

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.

Via Benzinga

Topics Intellectual Property

Should Politicians Be Allowed to Trade Stocks? The Big Debate

July 10, 2025

A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office? Amidst rising...

Via MarketMinute

Topics Artificial Intelligence Electric Vehicles

A Message to All Investors From Motley Fool CEO Tom Gardner ↗

July 10, 2025

Via The Motley Fool

Topics Artificial Intelligence

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

July 10, 2025

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.